Amgen Emerges as Potential Cytokinetics Suitor as Novartis Pulls Away: Reports

Novartis is reportedly backing off of its rumored potential acquisition of California–based cardiovascular disease specialist Cytokinetics, according to a Thursday report from The Wall Street Journal, citing a source familiar with the matter.